WARSAW, Ind., Sept. 13, 2017 /PRNewswire-iReach/ -- Nextremity Solutions, Inc., a Strategic Commercialization Organization (SCO) in the musculoskeletal space, located in Warsaw, IN, "The Orthopedic Capital of the World", announced that it has achieved record setting revenue for the first half of 2017.
Nextremity Solutions believes that the successes the Company is seeing are directly tied to its surgeon-driven i3TM Strategic Solutions product development strategy, as well as its distribution agreement with a worldwide strategic partner. In October of 2016, Nextremity Solutions announced it had finalized an exclusive global distribution agreement for its first four commercialized products, which address unmet clinical needs in forefoot elective surgery.
"Our i3 Strategic Solutions product development pipeline in the foot and ankle space remains strong and the company will begin to expand into other markets in 2018. Nextremity Solutions' team remains very excited as we continue to take the next steps to expand our product development portfolio and continue to pursue our mission of becoming recognized as the premier musculoskeletal Strategic Commercialization Organization (SCO). We have an amazing group of talented professionals who are passionate about creating innovative technology and solutions that advance the standard of care for surgeons and patients worldwide," stated Ryan Schlotterback, Chief Commercial Officer for Nextremity Solutions.
"The Company continues to be EBITDA positive as it heads into its second half of 2017 and is on track to achieve annual revenue forecasts. Our recent financial performance is the result of our team's hard work and dedication. Because of our mutually beneficial relationship with our strategic alliance partner, our team can focus strongly on our i3 Strategic Solutions strategy and continue to produce Revenue ReadyTM products and solutions that are beneficial to surgeons and patients worldwide," commented Rod K. Mayer, President and CEO of Nextremity Solutions.
Nextremity Solutions, recently announced the limited release of its newest product, the PiroVueTM Gastrocnemius Recession System for the treatment of equinus deformities in patients and plans to announce the limited release of yet another new product in Q4 2017.
To learn more about i3 Strategic Solutions, visit www.i3strategicsolutions.com.
If you're a surgeon inventor or have a product idea that you think would be a good fit for Nextremity Solutions, Inc., they can be contacted at 732-383-7901.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held Strategic Commercialization Organization (SCO) in the musculoskeletal space offering innovative solutions and approaches to unmet clinical needs in the mind of surgeons and for the benefit of patients worldwide.
For further information, visit www.nextremitysolutions.com or call Dave Temple, Executive Director of i3 Direct at 574-635-3023.
Media Contact: Dave Temple, Nextremity Solutions, Inc., 574-635-3023, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Nextremity Solutions, Inc.
Advertisement
Nextremity Solutions believes that the successes the Company is seeing are directly tied to its surgeon-driven i3TM Strategic Solutions product development strategy, as well as its distribution agreement with a worldwide strategic partner. In October of 2016, Nextremity Solutions announced it had finalized an exclusive global distribution agreement for its first four commercialized products, which address unmet clinical needs in forefoot elective surgery.
Advertisement
"Our i3 Strategic Solutions product development pipeline in the foot and ankle space remains strong and the company will begin to expand into other markets in 2018. Nextremity Solutions' team remains very excited as we continue to take the next steps to expand our product development portfolio and continue to pursue our mission of becoming recognized as the premier musculoskeletal Strategic Commercialization Organization (SCO). We have an amazing group of talented professionals who are passionate about creating innovative technology and solutions that advance the standard of care for surgeons and patients worldwide," stated Ryan Schlotterback, Chief Commercial Officer for Nextremity Solutions.
"The Company continues to be EBITDA positive as it heads into its second half of 2017 and is on track to achieve annual revenue forecasts. Our recent financial performance is the result of our team's hard work and dedication. Because of our mutually beneficial relationship with our strategic alliance partner, our team can focus strongly on our i3 Strategic Solutions strategy and continue to produce Revenue ReadyTM products and solutions that are beneficial to surgeons and patients worldwide," commented Rod K. Mayer, President and CEO of Nextremity Solutions.
Nextremity Solutions, recently announced the limited release of its newest product, the PiroVueTM Gastrocnemius Recession System for the treatment of equinus deformities in patients and plans to announce the limited release of yet another new product in Q4 2017.
To learn more about i3 Strategic Solutions, visit www.i3strategicsolutions.com.
If you're a surgeon inventor or have a product idea that you think would be a good fit for Nextremity Solutions, Inc., they can be contacted at 732-383-7901.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held Strategic Commercialization Organization (SCO) in the musculoskeletal space offering innovative solutions and approaches to unmet clinical needs in the mind of surgeons and for the benefit of patients worldwide.
For further information, visit www.nextremitysolutions.com or call Dave Temple, Executive Director of i3 Direct at 574-635-3023.
Media Contact: Dave Temple, Nextremity Solutions, Inc., 574-635-3023, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Nextremity Solutions, Inc.
